ライフサイエンスコーパス: abiraterone

1 nd treatment type (taxane vs enzalutamide or abiraterone).

2 a new hormonal agent (e.g., enzalutamide or abiraterone).

3 mour activity against xenograft tumours than abiraterone.

4 sociated with resistance to enzalutamide and abiraterone.

5 sociated with resistance to enzalutamide and abiraterone.

6 iating treatment with either enzalutamide or abiraterone.

7 the clinical efficacy of the CYP17 inhibitor abiraterone.

8 orted end points than either enzalutamide or abiraterone.

9 , bicalutamide, or greater concentrations of abiraterone.

10 ts (45.4%) in the cohort received first-line abiraterone.

11 aracterized with different concentrations of abiraterone.

12 All patients received abiraterone 1 g daily plus prednisone 10 mg and luteiniz

13 were randomly assigned (1:1) to receive oral abiraterone (1 g daily) plus prednisone (5 mg twice dail

14 ranulocyte colony-stimulating factor) versus abiraterone (1000 mg orally once daily plus 5 mg prednis

15 ly as abiraterone acetate (AA), a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testost

16 hich were obtained in the presence of either abiraterone, a first-in-class steroidal inhibitor recent

17 Abiraterone, a rationally designed inhibitor of CYP17A1

18 Unexplored electrochemical behavior of abiraterone, a recent and widely used prostate cancer dr

19 Abiraterone acetate is a prodrug of abiraterone, a selective inhibitor of CYP17, the enzyme

20 Abiraterone, a steroidal 17alpha-hydroxylase/17,20-lyase

21 The CYP17A1 inhibitor abiraterone abolished androgen secretion and reduced exp

22 Patients received oral abiraterone acetate (1 g) once daily and prednisone (5 m

23 a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5

24 Participants received oral doses of abiraterone acetate (1000 mg daily) and prednisone (5 mg

25 onse system in a 1:1 ratio to receive either abiraterone acetate (1000 mg once daily) plus prednisone

26 ents were randomly assigned (1:1) to receive abiraterone acetate (1000 mg) once daily orally plus pre

27 e randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twic

28 rednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patie

29 Abiraterone acetate (AA) is a potent and selective inhib

30 In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged o

31 not reduce serum androgens as effectively as abiraterone acetate (AA), a prodrug of abiraterone, a CY

32 Abiraterone acetate (ABI) and enzalutamide (ENZ) are con

33 en receptor signaling inhibitors (ARSi) like abiraterone acetate (Abi) and enzalutamide (Enza) or a f

34 this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was administered once daily

35 patients were also scheduled to receive oral abiraterone acetate 1000 mg once daily plus oral prednis

36 This is the first evidence that abiraterone acetate achieves sustained suppression of te

37 ls of novel hormonal agents, with a focus on abiraterone acetate and enzalutamide (MDV3100).

38 Abiraterone acetate and enzalutamide are recommended as

39 t of novel anti-androgen therapies including abiraterone acetate and enzalutamide.

40 Phase III data with abiraterone acetate and phase II data with MDV-3100, alo

41 te cancer previously treated with docetaxel, abiraterone acetate and prednisone offer significant ben

42 group were allowed to cross over to receive abiraterone acetate and prednisone plus ADT treatment as

43 ith clinically significant pain at baseline, abiraterone acetate and prednisone resulted in significa

44 7]; p=0.0056) were significantly better with abiraterone acetate and prednisone than with prednisone

45 -related event was significantly longer with abiraterone acetate and prednisone than with prednisone

46 Randomized, phase III trials of abiraterone acetate are underway to define the future ro

47 n, development of sustained side-effects, or abiraterone acetate becoming available in the respective

48 Fasted or fed cohorts received abiraterone acetate doses of 250, 500, 750, or 1,000 mg

49 This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics,

50 n this early-access protocol trial to assess abiraterone acetate for patients with metastatic castrat

51 n observed: 354 (65%) of 546 patients in the abiraterone acetate group and 387 (71%) of 542 in the pl

52 Overall, 365 (67%) patients in the abiraterone acetate group and 435 (80%) in the placebo g

53 all survival was significantly longer in the abiraterone acetate group than in the placebo group (34.

54 ac disorders (41 [8%] of 542 patients in the abiraterone acetate group vs 20 [4%] of 540 patients in

55 ce daily) plus prednisone (5 mg twice daily; abiraterone acetate group) or placebo plus prednisone (p

56 Abiraterone acetate has significant antitumor activity i

57 her support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive

58 01 to enable worldwide preapproval access to abiraterone acetate in patients with metastatic castrati

59 Abiraterone acetate is a first-line therapy for castrati

60 Abiraterone acetate is a prodrug of abiraterone, a selec

61 Abiraterone acetate is an effective treatment for metast

62 or men with metastatic CRPC, and approval of abiraterone acetate is anticipated based on the results

63 (P = 0.020) increase in expression following abiraterone acetate or enzalutamide therapy.

64 Abiraterone acetate plus prednisolone (herein referred t

65 Abiraterone acetate plus prednisolone improves survival

66 tamide, an androgen receptor antagonist, and abiraterone acetate plus prednisone (AAP) prolong surviv

67 (6.2%) on enzalutamide + ADT, 1262 (5.6%) on abiraterone acetate plus prednisone + ADT, and 11,961 (5

68 nt long-term survival outcomes and safety of abiraterone acetate plus prednisone and ADT from the fin

69 The abiraterone acetate plus prednisone and prednisone-alone

70 These findings support the use of abiraterone acetate plus prednisone as a standard of car

71 iving prednisone alone subsequently received abiraterone acetate plus prednisone as crossover per pro

72 occurred in three (<1%) patients each in the abiraterone acetate plus prednisone group (gastric ulcer

73 all survival was significantly longer in the abiraterone acetate plus prednisone group (median 53.3 m

74 atients were randomly assigned to either the abiraterone acetate plus prednisone group (n=597) or pla

75 7.0) and 618 deaths (275 [46%] of 597 in the abiraterone acetate plus prednisone group and 343 [57%]

76 was hypokalaemia (four [1%] patients in the abiraterone acetate plus prednisone group and none in th

77 e events were hypertension (125 [21%] in the abiraterone acetate plus prednisone group vs 60 [10%] in

78 prednisone (5 mg) once daily orally and ADT (abiraterone acetate plus prednisone group) or matching p

79 occurred in 192 (32%) of 597 patients in the abiraterone acetate plus prednisone group, 151 (25%) of

80 alysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival,

81 We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and

82 The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did

83 Abiraterone acetate plus prednisone or prednisolone impr

84 23 (n=401) or placebo (n=405) in addition to abiraterone acetate plus prednisone or prednisolone.

85 Abiraterone acetate plus prednisone significantly improv

86 Abiraterone acetate plus prednisone significantly improv

87 al analysis of the phase 3 COU-AA-301 study, abiraterone acetate plus prednisone significantly prolon

88 lyses of the LATITUDE study, the addition of abiraterone acetate plus prednisone to androgen deprivat

89 the randomised, phase 3 COU-AA-301 trial of abiraterone acetate plus prednisone versus placebo plus

90 he individual-patient level in this trial of abiraterone acetate plus prednisone versus prednisone al

91 randomized, double-blind phase III trial of abiraterone acetate plus prednisone versus prednisone al

92 The combination of abiraterone acetate plus prednisone with ADT was associa

93 72 patients who crossed over from placebo to abiraterone acetate plus prednisone) and hypokalaemia (7

94 ng/mL or lower within 12 months of starting abiraterone acetate plus prednisone.

95 Abiraterone acetate potently disrupts intracrine androge

96 The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among pat

97 llow-up of more than 4 years, treatment with abiraterone acetate prolonged overall survival compared

98 d to ascertain the most effective regimen of abiraterone acetate to optimise patients' outcomes.

99 Abiraterone acetate was well tolerated and demonstrated

100 Abiraterone acetate was well tolerated.

101 Abiraterone acetate with prednisolone should be consider

102 To determine the efficacy of abiraterone acetate with prednisone in these high-risk p

103 e clinical impact of the addition of BRIs to abiraterone acetate with prednisone in this disease sett

104 Abiraterone acetate with prednisone is currently the mos

105 Abiraterone acetate, 1000 mg, once daily by mouth with p

106 Abiraterone acetate, 1000 mg, once daily with prednisone

107 In the past year abiraterone acetate, a CYP17 (17alpha-hydroxylase/17, 20

108 with overexpressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks ster

109 Abiraterone acetate, an androgen biosynthesis inhibitor,

110 Journal of Medicine describe the utility of abiraterone acetate, an androgen biosynthesis inhibitor,

111 We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthes

112 al was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inh

113 A third agent, abiraterone acetate, an orally administered CYP17 inhibi

114 el CYP17 inhibitors, including ketoconazole, abiraterone acetate, and VN/124-1, which are agents curr

115 for these patients have expanded to include abiraterone acetate, cabazitaxel and enzalutamide.

116 ancer starting any treatment with docetaxel, abiraterone acetate, enzalutamide, or radium Ra 223 dich

117 The development of cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and sipul

118 5%) of the 40 received PRO-related labeling (abiraterone acetate, ruxolitinib phosphate, and crizotin

119 8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo

120 alemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo

121 l patients who received at least one dose of abiraterone acetate.

122 ecline in CTCs after starting treatment with abiraterone acetate.

123 , and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium

124 Abiraterone acetate/prednisone, enzalutamide, or (223)Ra

125 Among patients receiving first-line abiraterone, African American men had higher median over

126 reduced by TOK-001 and to a lesser extent by abiraterone alcohol, and suggest a mechanism by which ca

127 In a clinical trial of abiraterone alone, followed by abiraterone plus dutaster

128 The P450 17A1 inhibitor abiraterone also bound to P450 17A1 in a multistep manne

129 an the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resista

130 e methylation of the B-ring carbocycle of an abiraterone analogue.

131 9%] with other or unknown race) who received abiraterone and 311 patients (median [IQR] age, 74 [69-7

132 bitors (APIs) such as Enzalutamide (ENZ) and Abiraterone and arises via a reversible trans-differenti

133 a 5alpha-reductase inhibitor), 3-keto-5alpha-abiraterone and downstream metabolites were depleted by

134 ard of care (n=454) or standard of care plus abiraterone and enzalutamide (n=462) in the abiraterone

135 orrelated with poor outcomes from the use of abiraterone and enzalutamide in patients with castration

136 However, resistance to abiraterone and enzalutamide limits this efficacy in mos

137 ombination-therapy and control groups of the abiraterone and enzalutamide trial, respectively.

138 abiraterone and enzalutamide (n=462) in the abiraterone and enzalutamide trial.

139 radiation (alpharadin) and hormone therapy (abiraterone and enzalutamide) agents has created a range

140 R activity in CRPC, mechanisms of action for abiraterone and enzalutamide, and possible mechanisms of

141 ese agents, the androgen-pathway inhibitors, abiraterone and enzalutamide, are shown to decrease the

142 sis and androgen-receptor signaling, such as abiraterone and enzalutamide, respectively.

143 ate cancer (mCRPC) undergoing treatment with abiraterone and enzalutamide, two drugs used to treat ad

144 PC) with next-generation endocrine therapies abiraterone and enzalutamide.

145 PCa cohorts exhibit increased resistance to Abiraterone and Enzalutamide.

146 tent second-generation AR-targeted therapies abiraterone and enzalutamide.

147 al trials, secondary hormonal agents such as abiraterone and MDV3100 may still be very effective in t

148 n therapies including CRPC therapies such as abiraterone and MDV3100.

149 e cohort, while two additional cohorts (post-abiraterone and newly castration-resistant prostate canc

150 nced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with signifi

151 lutamide and leuprolide (EL) with or without abiraterone and prednisone (ELAP) before radical prostat

152 ed targeted plasma levels when combined with abiraterone and prednisone, and was well tolerated.

153 d therapies targeting AR signalling, such as abiraterone and second-generation anti-androgens includi

154 ing synthetic inhibitors, including the drug abiraterone and the natural substrate pregnenolone, in t

155 progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role

156 17A1 and 17A2 were obtained with the ligand abiraterone and with Prog for P450 17A2.

157 rior docetaxel (84%), cabazitaxel (48%), and abiraterone and/or enzalutamide (90%).

158 n with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide were randomly assigned a

159 and progressive disease after docetaxel and abiraterone and/or enzalutamide.

160 l efficacy of androgen synthesis inhibitors (abiraterone) and novel, second-generation AR antagonists

161 D4A in patients with prostate cancer taking abiraterone, and is an androgen receptor agonist, which

162 to improve survival with the lyase inhibitor abiraterone, and lead to prostate-specific antigen and o

163 Similarly, among men receiving abiraterone, AR-V7-positive patients had lower PSA respo

164 CYP17A1, so that CYP17A1 inhibitors such as abiraterone are effective therapies for CRPC.

165 TOK-001 and abiraterone are potent 17-heteroarylsteroid (17-HAS) inh

166 Abiraterone blocks androgen synthesis and prolongs survi

167 ain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a tran

168 Abiraterone can be further metabolized in vivo on the st

169 istant PCa commencing either enzalutamide or abiraterone (cohort 2).

170 or the physician's choice of enzalutamide or abiraterone (control).

171 ancer, with the recently developed inhibitor abiraterone currently in advanced clinical trials.

172 ted by an enzyme to the more active Delta(4)-abiraterone (D4A), which blocks multiple steroidogenic e

173 erone is metabolized in patients to Delta(4)-abiraterone (D4A), which has even greater anti-tumour ac

174 umerically larger declines than those taking abiraterone, differences were small and clinically unimp

175 Simulations with standard abiraterone dosing demonstrate strong selection for andr

176 Abiraterone, enzalutamide, and other agents can improve

177 Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, do

178 ADT plus docetaxel, abiraterone, enzalutamide, or apalutamide should be offe

179 ived ADT plus docetaxel and 52 (3%) received abiraterone, enzalutamide, or apalutamide.

180 ger in patients who received radium-223 plus abiraterone, enzalutamide, or both (median NA, 95% CI 16

181 urvival in patients treated with concomitant abiraterone, enzalutamide, or denosumab require confirma

182 Therefore, an increase in abiraterone exposure could reverse resistance secondary

183 In patients treated with enzalutamide and/or abiraterone FASN/AR-V7 double-positive metastases were f

184 ens, has been exemplified by the approval of abiraterone for the treatment of castration-resistant pr

185 nd -1.20 (-4.15 to 1.74) in the placebo plus abiraterone group (difference 1.30, 95% CI -2.70 to 5.30

186 (95% CI -2.50 to 2.71) in the olaparib plus abiraterone group and -1.20 (-4.15 to 1.74) in the place

187 lled; 554 (50%) were assigned to the placebo-abiraterone group and 547 (50%) to the ipatasertib-abira

188 erone group and 547 (50%) to the ipatasertib-abiraterone group.

189 Although abiraterone has been previously described as showing slo

190 The introduction of enzalutamide and abiraterone has led to improvement in the treatment of m

191 Abiraterone improved radiographic progression-free survi

192 ary end point of OS in a randomized trial of abiraterone in patients with mCRPC.

193 provide further support for the efficacy of abiraterone in this population.

194 and CRPC xenografts treated with MDV3100 or abiraterone, increased expression of two constitutively

195 Abiraterone inhibited in vitro proliferation and AR-regu

196 Further, we observed that seviteronel and abiraterone inhibited the growth of tumor xenografts exp

197 urvival advantage in CRPC for treatment with abiraterone (inhibitor of the enzyme CYP17A1 required fo

198 Abiraterone is a standard treatment for metastatic castr

199 We hypothesized that abiraterone is converted by an enzyme to the more active

200 Here we show that abiraterone is converted to D4A in mice and patients wit

201 astration-resistant prostate cancer (mCRPC), abiraterone is effective.

202 Abiraterone is metabolized in patients to Delta(4)-abira

203 Abiraterone is structurally similar to the substrates of

204 TOK-001, but not abiraterone, is an effective apparent competitor of the

205 ial 5alpha-reduced metabolite, 3-keto-5alpha-abiraterone, is present at higher concentrations than D4

206 V7-negative men, taxanes and enzalutamide or abiraterone may have comparable efficacy.

207 we hypothesized that progressive disease on abiraterone may occur secondary to glucocorticoid-induce

208 nonetheless, expectations for other agents (Abiraterone, MDV3100, Zibotentan, immunotherapy agents)

209 ly specific method of clinically fine-tuning abiraterone metabolism to optimize therapy.

210 armacological 5alpha-reductase inhibition on abiraterone metabolism.

211 [66.7%] with some postsecondary education), abiraterone (n = 29) (mean [SD] age, 76.2 [7.2] years; 1

212 ard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial.

213 nd randomly assigned to receive olaparib and abiraterone (n=71) or placebo and abiraterone (n=71).

214 aparib and abiraterone (n=71) or placebo and abiraterone (n=71).

215 01 is a consistently superior inhibitor than abiraterone of R1881-induced transcriptional activity of

216 rior docetaxel (84%), cabazitaxel (48%), and abiraterone or enzalutamide (92%).

217 ith cabazitaxel and 8.5 months (4.9-NE) with abiraterone or enzalutamide (hazard ratio [HR] 0.55, 95%

218 h cabazitaxel and 16.7 months (10.8-NE) with abiraterone or enzalutamide (HR 0.59, 95% CI 0.35-1.01;

219 ith cabazitaxel and 8.9 months (6.3-NE) with abiraterone or enzalutamide (HR 0.72, 95% CI 0.44-1.20;

220 randomly assigned to cabazitaxel (n=129) or abiraterone or enzalutamide (n=126).

221 abazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p<0.0001).

222 ty index score in favour of cabazitaxel over abiraterone or enzalutamide (p=0.030) but no difference

223 ely enrolled 202 patients with CRPC starting abiraterone or enzalutamide and investigated the prognos

224 g BRCA2 carriers treated in first line with abiraterone or enzalutamide compared with taxanes.

225 on-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic

226 eatment from mCRPC patients receiving either abiraterone or enzalutamide in the pre- or post-chemothe

227 nrolled 118 men with mCRPC who were starting abiraterone or enzalutamide treatment.

228 sis ( P = .01), higher PSA ( P < .01), prior abiraterone or enzalutamide use ( P = .03), prior taxane

229 um, number of prior hormone therapies, prior abiraterone or enzalutamide use, prior taxane use, prese

230 s while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.

231 nd an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at

232 h the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastati

233 th an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastati

234 androgen receptor signaling inhibitor (ARSI; abiraterone or enzalutamide), we examined the associatio

235 ternative androgen-signaling-targeted agent (abiraterone or enzalutamide).

236 atment with docetaxel, 49 (98%) had received abiraterone or enzalutamide, and 29 (58%) had received c

237 ntly associated with shorter PFS and OS with abiraterone or enzalutamide, and such men with mCRPC sho

238 CTCs associated with disease progression on abiraterone or enzalutamide, including mesenchymal pheno

239 rior second-line antiandrogen treatment with abiraterone or enzalutamide, prior chemotherapy, and pri

240 that radium-223 can be safely combined with abiraterone or enzalutamide, which are now both part of

241 metastases; investigational site; and prior abiraterone or enzalutamide.

242 ibited by anti-androgen therapies, including abiraterone or enzalutamide.

243 raphic evidence, and previous treatment with abiraterone or enzalutamide.

244 s act through inhibiting androgen synthesis (abiraterone) or blocking ligand binding (enzalutamide).

245 ate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of andro

246 ical trial of abiraterone alone, followed by abiraterone plus dutasteride (a 5alpha-reductase inhibit

247 Abiraterone plus luteinizing hormone-releasing hormone a

248 intensity was longer in patients assigned to abiraterone plus prednisone (26.7 months [95% CI 19.3-no

249 ogression of worst pain was also longer with abiraterone plus prednisone (26.7 months [95% CI 19.4-no

250 nderwent randomisation: 546 were assigned to abiraterone plus prednisone and 542 to placebo plus pred

251 or the physician's choice of enzalutamide or abiraterone plus prednisone as the control therapy (131

252 who were assigned to receive enzalutamide or abiraterone plus prednisone as the control therapy, desp

253 naling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutam

254 Abiraterone plus prednisone delays patient-reported pain

255 randomly assigned 796 patients with mCRPC to abiraterone plus prednisone or prednisolone with either

256 of 1,088 patients were randomly assigned to abiraterone plus prednisone or prednisone alone.

257 stases and minimal symptoms, enzalutamide or abiraterone plus prednisone should be offered after disc

258 rioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to pl

259 ified by ETS status and randomly assigned to abiraterone plus prednisone without (arm A) or with veli

260 ew was 0.43 (95% CI, 0.35 to 0.52; P < .001; abiraterone plus prednisone: median rPFS, not estimable;

261 2 months, overall survival was improved with abiraterone-prednisone (median not reached, vs. 27.2 mon

262 ogression-free survival was 16.5 months with abiraterone-prednisone and 8.3 months with prednisone al

263 group versus 16.6 months (13.9-19.3) in the abiraterone-prednisone group (hazard ratio [HR] 0.69, 95

264 s (95% CI 19.4-27.4) in the apalutamide plus abiraterone-prednisone group versus 16.6 months (13.9-19

265 Abiraterone-prednisone showed superiority over prednison

266 nths with prednisone alone (hazard ratio for abiraterone-prednisone vs. prednisone alone, 0.53; 95% c

267 lutamide plus abiraterone-prednisone; 490 to abiraterone-prednisone).

268 liver-function testing were more common with abiraterone-prednisone.

269 014 to Aug 30, 2016 (492 to apalutamide plus abiraterone-prednisone; 490 to abiraterone-prednisone).

270 or cells with resistance to enzalutamide and abiraterone raise the possibility of extending the use o

271 We demonstrate that both TOK-001 and abiraterone reduced AR protein and mRNA expression, and

272 Adding olaparib to abiraterone resulted in increased toxicity, including an

273 tor, providing an additional explanation for abiraterone's clinical activity.

274 nation-conversion to a more active agent-for abiraterone's survival extension.

275 Comparison of the two fish P450 17A-abiraterone structures with human P450 17A1 showed only

276 ults with next generation drugs (MDV3100 and abiraterone) that inhibit androgen receptor (AR) signali

277 ver, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short

278 r with taxanes compared with enzalutamide or abiraterone therapy in AR-V7-positive men, whereas outco

279 with primary resistance to enzalutamide and abiraterone therapy, but the relevance of AR-V7 status i

280 to be more efficacious than enzalutamide or abiraterone therapy, whereas in AR-V7-negative men, taxa

281 higher in taxane-treated vs enzalutamide- or abiraterone-treated men (41% vs 0%; P < .001), and PSA P

282 l of 31 enzalutamide-treated patients and 31 abiraterone-treated patients were enrolled, of whom 39%

283 Abiraterone treatment alone caused defects in mitotic sp

284 Abiraterone treatment increased SLCO1B3 expression in 22

285 Abiraterone treatment induces mitotic defects that sensi

286 pendent de novo androgen synthesis, and that abiraterone treatment of these xenografts imposes select

287 promiscuous AR T878A in patients with prior abiraterone treatment.

288 D4A would be more clinically effective than abiraterone treatment.

289 Abiraterone treats metastatic castrate-resistant prostat

290 ombination-therapy and control groups of the abiraterone trial, respectively, and 298 (58%) of 513 pa

291 dard of care plus abiraterone (n=501) in the abiraterone trial.

292 vs first-line enzalutamide (hazard ratio for abiraterone vs enzalutamide: non-Hispanic White men, 1.2

293 treatment interaction existed for first-line abiraterone vs first-line enzalutamide (hazard ratio for

294 of 62 patients treated with enzalutamide or abiraterone, we also investigated the interaction betwee

295 y demonstrated the direct electroactivity of abiraterone when reacting with MWCNT as well as an elect

296 sociate with a reduced clinical benefit from abiraterone when these tumors progress.

297 FDA has approved only one CYP17A1 inhibitor, abiraterone, which contains a steroidal scaffold similar

298 Abiraterone, which targets host desmolase (CYP17A1), a r

299 d in castrate-resistant men (enzalutamide or abiraterone) with metastatic PCa.

300 nonetheless, expectations for other agents (abiraterone, zibotentan, Provenge) still remain high.